{"entity":{"id":"idea-fund-shelved-asset-escrow","kind":"idea","name":"Automatic offer of shelved cancer assets to non-profits after two years","aka":[],"tldr":"When a company stops developing a cancer drug for business rather than safety reasons and leaves it idle for two years, it would be obliged to offer the rights, data package and remaining drug supply to qualified non-profit or academic developers on pre-set terms, keeping the right to resume. This turns the stalled-asset registry's listing into a duty.","summary":"A legal or funder-imposed condition (for example on drugs that received public research funding, orphan designation or tax credits) that oncology assets discontinued for non-safety reasons and not actively developed for two years must be offered for licence to qualified non-profit or academic developers on pre-set terms (non-exclusive for research, exclusive for defined rare indications, modest royalties on commercialisation). Data packages and remaining drug supply are included. Companies retain rights to resume. This complements the stalled-asset registry by creating a duty, not just a listing.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Secrecy and intellectual property block collaboration): Danchev et al., Evaluation of data sharing after implementation of the ICMJE data sharing statement requirement (JAMA Netw Open 2021)","url":"https://doi.org/10.1001/jamanetworkopen.2020.33972"}],"tags":[],"related":["idea-fund-stalled-asset-registry","idea-fund-nonprofit-pharma","idea-fund-repurposing-indication-exclusivity","tiragolumab","magrolimab"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-ip-collaboration","b-translational-valley","b-rare-cancers"],"keyPapers":["paper-danchev-jama-netw-open"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"An escrow duty leads to at least ten shelved oncology assets entering non-profit or academic development within three years and at least one reaching a registration trial in a rare or paediatric indication within six.","rationale":"Many discontinued assets have adequate safety data and mechanistic rationale in indications the owner never pursued; academic groups routinely identify such assets but cannot obtain them. Use-it-or-lose-it provisions exist in patent law (compulsory licensing for non-working) and in orphan drug regulation (revocation for insufficient supply).","test":"Apply the condition to publicly co-funded assets in one jurisdiction and track offers, licences and subsequent trials over three years.","maturity":"speculative","actor":"policy","cost":"small","horizonYears":3},"route":"/ideas/idea-fund-shelved-asset-escrow/","neighbours":{"idea":[{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/"},{"id":"idea-fund-stalled-asset-registry","kind":"idea","name":"A public registry of stalled academic assets and shelved company compounds","route":"/ideas/idea-fund-stalled-asset-registry/"},{"id":"idea-fund-repurposing-indication-exclusivity","kind":"idea","name":"A repurposing label pathway with short exclusivity that non-profits can hold","route":"/ideas/idea-fund-repurposing-indication-exclusivity/"}],"drug":[{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/"},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"paper":[{"id":"paper-danchev-jama-netw-open","kind":"paper","name":"Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement","route":"/key-papers/paper-danchev-jama-netw-open/"}]}}